FibroGen Cash Flows Other Operating vs Begin Period Cash Flow Analysis
| FGEN Stock | USD 0.41 0.01 2.38% |
FibroGen financial indicator trend analysis is much more than just examining FibroGen latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether FibroGen is a good investment. Please check the relationship between FibroGen Cash Flows Other Operating and its Begin Period Cash Flow accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroGen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in FibroGen Stock, please use our How to Invest in FibroGen guide.
Cash Flows Other Operating vs Begin Period Cash Flow
Cash Flows Other Operating vs Begin Period Cash Flow Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of FibroGen Cash Flows Other Operating account and Begin Period Cash Flow. At this time, the significance of the direction appears to have almost no relationship.
The correlation between FibroGen's Cash Flows Other Operating and Begin Period Cash Flow is 0.13. Overlapping area represents the amount of variation of Cash Flows Other Operating that can explain the historical movement of Begin Period Cash Flow in the same time period over historical financial statements of FibroGen, assuming nothing else is changed. The correlation between historical values of FibroGen's Cash Flows Other Operating and Begin Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash Flows Other Operating of FibroGen are associated (or correlated) with its Begin Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Begin Period Cash Flow has no effect on the direction of Cash Flows Other Operating i.e., FibroGen's Cash Flows Other Operating and Begin Period Cash Flow go up and down completely randomly.
Correlation Coefficient | 0.13 |
| Relationship Direction | Positive |
| Relationship Strength | Insignificant |
Cash Flows Other Operating
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Most indicators from FibroGen's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into FibroGen current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroGen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in FibroGen Stock, please use our How to Invest in FibroGen guide.As of the 4th of December 2024, Selling General Administrative is likely to drop to about 82.7 M. In addition to that, Tax Provision is likely to drop to about 29.4 K
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 2.2M | 1.4M | 15.5M | 16.3M | Depreciation And Amortization | 14.8M | 10.6M | 9.9M | 7.2M |
FibroGen fundamental ratios Correlations
Click cells to compare fundamentals
FibroGen Account Relationship Matchups
High Positive Relationship
High Negative Relationship
FibroGen fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 857.4M | 826.8M | 773.8M | 610.1M | 423.5M | 665.2M | |
| Short Long Term Debt Total | 67.9M | 37.7M | 99.7M | 89.9M | 170.5M | 89.2M | |
| Other Current Liab | 83.8M | 118.9M | 149.0M | 224.8M | 166.3M | 84.4M | |
| Total Current Liabilities | 102.7M | 163.2M | 225.5M | 273.6M | 217.7M | 128.8M | |
| Total Stockholder Equity | 516.1M | 422.2M | 209.1M | (21.4M) | (204.2M) | (194.0M) | |
| Other Liab | 162.8M | 178.1M | 212.8M | 241.4M | 277.6M | 147.1M | |
| Property Plant And Equipment Net | 82.3M | 63.3M | 120.2M | 100.5M | 81.4M | 89.5M | |
| Current Deferred Revenue | 490K | 6.5M | 15.9M | 13.1M | 12.7M | 10.0M | |
| Net Debt | (75.2M) | (640.7M) | (71.5M) | (65.8M) | 56.8M | 59.6M | |
| Retained Earnings | (784.7M) | (974.0M) | (1.3B) | (1.6B) | (1.8B) | (1.7B) | |
| Accounts Payable | 6.1M | 24.8M | 26.1M | 30.8M | 18.0M | 13.0M | |
| Cash | 126.3M | 678.4M | 171.2M | 155.7M | 113.7M | 108.0M | |
| Non Current Assets Total | 154.9M | 71.7M | 299.8M | 117.3M | 92.0M | 146.7M | |
| Non Currrent Assets Other | 11.4M | 5.5M | 8.0M | 7.4M | 5.3M | 6.5M | |
| Other Assets | 9.5M | 38.1M | 8.0M | 6.9M | 1.0 | 0.95 | |
| Long Term Debt | 17.2M | 16.8M | 16.8M | 71.9M | 64.7M | 46.3M | |
| Cash And Short Term Investments | 533.8M | 686.5M | 405.2M | 422.0M | 235.6M | 404.9M | |
| Net Receivables | 28.5M | 41.9M | 25.4M | 16.3M | 41.1M | 26.7M | |
| Common Stock Total Equity | 854K | 877K | 914K | 929K | 1.1M | 716.1K | |
| Common Stock Shares Outstanding | 86.6M | 89.9M | 92.3M | 93.6M | 97.3M | 78.2M | |
| Short Term Investments | 407.5M | 8.1M | 234.0M | 266.3M | 121.9M | 165.1M | |
| Liabilities And Stockholders Equity | 857.4M | 826.8M | 773.8M | 610.1M | 423.5M | 665.2M | |
| Non Current Liabilities Total | 219.2M | 222.2M | 319.2M | 338.0M | 368.1M | 261.8M | |
| Other Current Assets | 133.4M | 10.2M | 12.5M | 14.1M | 13.4M | 19.5M | |
| Other Stockholder Equity | 1.3B | 1.4B | 1.5B | 1.5B | 1.6B | 1.0B | |
| Total Liab | 322.0M | 385.4M | 544.7M | 611.6M | 585.7M | 390.6M | |
| Property Plant And Equipment Gross | 82.3M | 63.3M | 120.2M | 100.5M | 253.1M | 138.8M | |
| Total Current Assets | 702.5M | 755.1M | 474.1M | 492.8M | 331.6M | 463.5M | |
| Accumulated Other Comprehensive Income | (747K) | (4.5M) | (4.2M) | (5.7M) | (6.9M) | (6.5M) | |
| Short Term Debt | 12.4M | 13.5M | 21.9M | 10.3M | 14.1M | 20.2M | |
| Common Stock | 877K | 914K | 929K | 942K | 988K | 773.7K | |
| Property Plant Equipment | 42.7M | 33.6M | 120.2M | 100.9M | 90.8M | 86.7M | |
| Net Tangible Assets | 516.1M | 422.2M | 209.1M | (21.4M) | (19.3M) | (18.3M) | |
| Long Term Investments | 61.1M | 244K | 171.6M | 9.4M | 5.3M | 5.0M | |
| Retained Earnings Total Equity | (715.8M) | (784.7M) | (974.0M) | (1.3B) | (1.1B) | (1.2B) | |
| Capital Surpluse | 1.2B | 1.3B | 1.4B | 1.5B | 1.7B | 1.2B |
Pair Trading with FibroGen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if FibroGen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in FibroGen will appreciate offsetting losses from the drop in the long position's value.Moving against FibroGen Stock
The ability to find closely correlated positions to FibroGen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace FibroGen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back FibroGen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling FibroGen to buy it.
The correlation of FibroGen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as FibroGen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if FibroGen moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for FibroGen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroGen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in FibroGen Stock, please use our How to Invest in FibroGen guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroGen. If investors know FibroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroGen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.536 | Earnings Share (1.23) | Revenue Per Share 1.758 | Quarterly Revenue Growth 0.143 | Return On Assets (0.27) |
The market value of FibroGen is measured differently than its book value, which is the value of FibroGen that is recorded on the company's balance sheet. Investors also form their own opinion of FibroGen's value that differs from its market value or its book value, called intrinsic value, which is FibroGen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroGen's market value can be influenced by many factors that don't directly affect FibroGen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroGen's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroGen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroGen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.